Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $56.57.

Several analysts recently commented on the company. Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 price target on the stock. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently bought and sold shares of AGIO. Summit Investment Advisors Inc. boosted its holdings in shares of Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 394 shares during the last quarter. Federated Hermes Inc. grew its holdings in Agios Pharmaceuticals by 4.4% in the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 582 shares in the last quarter. KBC Group NV increased its stake in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Agios Pharmaceuticals by 6.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock worth $539,000 after acquiring an additional 688 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Agios Pharmaceuticals by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company’s stock valued at $2,021,000 after acquiring an additional 708 shares during the last quarter.

Agios Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ:AGIO opened at $30.84 on Friday. Agios Pharmaceuticals has a twelve month low of $27.14 and a twelve month high of $62.58. The company has a market cap of $1.77 billion, a PE ratio of 2.72 and a beta of 0.90. The company’s 50 day moving average is $33.21 and its 200 day moving average is $40.97.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.